Stephen G. Grygiel is a partner and co-chair of the Keefe Bartels Class Action Department. Steve Grygiel's class action and complex litigation practice focuses primarily on pharmaceutical and cost-recovery litigation, securities and corporate governance.

Steve has successfully litigated and tried shareholder dissolution and shareholder rights cases and injunction actions, bankruptcy court adversary proceedings (recoupment and debtor fraud), and other corporate and commercial matters. These include In re Sprint Corp. Shareholders Litig. (Dist. Ct., Johnson Cty., Kansas, 04-CV-01714) (tracking stock recombination; $57.5 Million settlement); In re New York Stock Exchange/Archipelago Merger Litig. (N.Y. Sup. Ct., Index No. 601646/05); In re Marsh & McLennan Companies, Inc. Sec. Litig. (S.D.N.Y. 04-CV-08144)((securities fraud; $400 Million Settlement); In La. Mun. Police and Employees Retirement System, et al. on behalf of Shareholders of Caremark RX (Del. Ct. Chan. 2635-CC).
Steve has written and spoken on numerous topics, including the implications of the Supreme Court's Twombly and Iqbal rulings for third party payor cost-recovery pharmaceutical litigation, the Class Action Fairness Act, and the Supreme Court's Tellabs decision.

AV rated by Martindale-Hubbell, Steve graduated from Hamilton College (magna cum laude, Phi Beta Kappa, 1979) and from Harvard Law School (1986). Steve clerked for the Chief Justice of Maine's Supreme Judicial Court before entering practice.